Condition: Atopic Dermatitis · Sponsor: Forte Biosciences, Inc.
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| First OC Dermatology | Fountain Valley, California, United States | — |
| Center for Dermatology Clinical Research, Inc. | Fremont, California, United States | — |
| Multi-Specialty Research Associates, Inc. | Lake City, Florida, United States | — |
| MedaPhase, Inc. | Newnan, Georgia, United States | — |
| DS Research | Clarksville, Indiana, United States | — |
| The Indiana Clinical Trials Center | Plainfield, Indiana, United States | — |
| DS Research | Louisville, Kentucky, United States | — |
| Lawrence J. Green MD LLC | Rockville, Maryland, United States | — |
| Minnesota Clinical Study Center | New Brighton, Minnesota, United States | — |
| Midwest Children's Health Research Institute | Lincoln, Nebraska, United States | — |
| Dermatology Consulting Services, PLLC | High Point, North Carolina, United States | — |
| Cyn3rgy Research | Gresham, Oregon, United States | — |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504279